Sales of the AIDS drug Fuzeon plunged in the first quarter of this year, pharmaceutical firm said after the markets closed Wednesday.

Trimeris (Nasdaq: TRMS) sells Fuzeon in partnership with drug giant Roche.

Fuzeon sales were $27.8 million for the first three months of the quarter, down 35 percent from $42.7 million for the same quarter in 2008.

U.S. and Canada sales dropped to $10 million, down 41 percent from a year ago.

The company issued no further comment other than to say it would disclose quarterly earnings early next month.

The first quarter totals reflected sharp declines from the third quarter of last year when global net sales reached $45.5 million. In the fourth quarter, sales dipped to $40.5 million.